Cardio Diagnostics Holdings Warrant (CDIOW) Financials
Newest figures come from the 10-Q for Q3 FY2026, filed Nov 6, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the CDIOW SEC filings page.
Cardio Diagnostics Holdings Inc. Warrant (CDIOW) reported $15K in revenue over the twelve months to Sep 30, 2026, down 3.8% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 5 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings.
Financing, not customer revenue, is carrying a development-stage operation whose heavy investment still produces recurring cash losses.
In FY2025, the net loss of$6.5M was closely reflected in operating cash flow of-$5.7M , indicating that accounting losses broadly represent operating cash consumption rather than merely non-cash charges. Free cash flow of-$5.9M was only modestly below operating cash flow after capital expenditures of$187K , so investment spending is not the main source of the cash deficit.
Revenue fell
Liabilities were just
Financial Health Signals
We do not publish a peer-relative financial health score for Cardio Diagnostics Holdings Inc. Warrant, because the score only covers companies whose filings and listing give us what it needs to compare them with their peers. The signals and metrics below are current.
Cardio Diagnostics Holdings Inc. Warrant passes 2 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 1 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, the one computable operating efficiency signal (asset turnover improving) does not pass.
Cardio Diagnostics Holdings Inc. Warrant reported a net loss of $6.5M while operations used $5.7M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Cardio Diagnostics Holdings Inc. Warrant reported an operating loss of $6.5M against $15K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Cardio Diagnostics Holdings Inc. Warrant generated $4K in revenue in Q3 2026. This represents an increase of 25.7% from the same quarter a year earlier. Against the prior quarter it is down 33.0%.
Cardio Diagnostics Holdings Inc. Warrant's EBITDA was -$1.7M in Q3 2026, measuring earnings before interest, taxes, depreciation, and amortization. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Cardio Diagnostics Holdings Inc. Warrant reported a net loss of $1.7M in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Cardio Diagnostics Holdings Inc. Warrant earned -$0.59 per diluted share (EPS) in Q3 2026. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Cash & Balance Sheet
Cardio Diagnostics Holdings Inc. Warrant recorded an outflow of $1.5M in free cash flow in Q3 2026, representing a cash shortfall after capex. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Cardio Diagnostics Holdings Inc. Warrant held $0 in cash as of Q3 2026; no long-term debt figure is on record for that period.
Not reported for Q3 2026.
Margins & Returns
Cardio Diagnostics Holdings Inc. Warrant's quarterly ROE was -30.3% in Q3 2026: one quarter's net income over shareholder equity, not annualized. This is down 9.3 percentage points from the same quarter a year earlier. Against the prior quarter it is down 10.1 percentage points.
Not reported for Q3 2026.
Not shown for Q3 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not shown for Q3 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Capital Allocation
Cardio Diagnostics Holdings Inc. Warrant invested $174K in research and development in Q3 2026. This represents a decrease of 7.8% from the same quarter a year earlier. Against the prior quarter it is up 6.9%.
Cardio Diagnostics Holdings Inc. Warrant reported no capital expenditure in Q3 2026. This represents a decrease of 100.0% from the same quarter a year earlier. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Not reported for Q3 2026.
CDIOW Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'25Filing | Q3'25Filing | Q2'2510-Q | Q1'2510-Q | Q4'24Filing |
|---|---|---|---|---|---|---|---|---|
| Revenue | $4K+25.7% | $5K-28.3% | $3K+185.1% | $4K-21.2% | $3K-56.6% | $7K-5.0% | $940-94.1% | $5K-15.0% |
| R&D Expenses | $174K-7.8% | $163K-8.7% | $130K+9.3% | $155K+2589.2% | $189K+3503.0% | $179K+2352.4% | $119K+995.8% | $6K-23.1% |
| SG&A Expenses | $1.6M-9.4% | $1.3M-20.8% | $1.7M+12.6% | $925K-28.3% | $1.7M+21.1% | $1.7M+30.7% | $1.5M-64.7% | $1.3M |
| Operating Income | -$1.7Mn/m | -$1.5Mn/m | -$1.8Mn/m | -$1.5Mn/m | -$1.7Mn/m | -$1.7Mn/m | -$1.6Mn/m | -$1.5Mn/m |
| EBITDA | -$1.7Mn/m | -$1.5Mn/m | -$1.8Mn/m | -$1.5Mn/m | -$1.7Mn/m | -$1.7Mn/m | -$1.6Mn/m | -$1.5M |
| Interest Expense | $2K-26.7% | $3K-26.7% | $3K-26.7% | $2K-26.7% | $3K-19.4% | $5K-19.4% | $5K-19.4% | $3K |
| Net Income | -$1.7Mn/m | -$1.5Mn/m | -$1.8Mn/m | -$1.5Mn/m | -$1.7Mn/m | -$1.7Mn/m | -$1.6Mn/m | -$1.5Mn/m |
| EPS (Basic) | -$0.59 | -$0.51 | -$0.63 | -$0.80 | -$0.98 | -$0.97 | -$0.97 | -$0.28 |
| EPS (Diluted) | -$0.59 | -$0.51 | -$0.63 | -$0.80 | -$0.98 | -$0.97 | -$0.97 | -$0.28 |
| Diluted Shares (Avg) | 3M | 3M | 3M | N/A | 2M | 2M | 2M | N/A |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, Income Tax.
CDIOW Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'25Filing | Q3'25Filing | Q2'2510-Q | Q1'2510-Q | Q4'24Filing |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $6.1M-30.8% | $7.9M-23.8% | $9.6M-22.2% | $7.8M-26.8% | $8.8M+96.1% | $10.4M+160.1% | $12.3M+183.8% | $10.6M+137.9% |
| Current Assets | $4.4M-37.1% | $6.2M-29.2% | $7.7M-26.5% | $5.9M-32.6% | $6.9M+163.7% | $8.7M+307.0% | $10.5M+306.9% | $8.8M+217.9% |
| Cash & Equivalents | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Short-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Accounts Receivable | $4K-68.4% | $4K-69.8% | $4K-55.3% | $8K-56.3% | $11K-20.4% | $13K+71.9% | $10K-49.7% | $19K+275.2% |
| Long-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Total Liabilities | $366K-42.6% | $500K-25.6% | $656K-27.5% | $793K-25.0% | $637K-19.9% | $672K-27.2% | $905K-29.9% | $1.1M-29.7% |
| Current Liabilities | $250K-37.4% | $359K-2.8% | $491K-9.1% | $605K-4.3% | $398K+29.1% | $370K-1.7% | $541K-21.2% | $632K-24.9% |
| Non-Current Liabilities | $116K-51.3% | $141K-53.5% | $165K-54.8% | $188K-55.8% | $239K-50.9% | $302K-44.7% | $364K-39.8% | $426K-35.8% |
| Total Equity | $5.7M-29.9% | $7.4M-23.6% | $8.9M-21.7% | $7.0M-27.0% | $8.2M+121.1% | $9.7M+216.3% | $11.4M+274.6% | $9.6M+223.1% |
| Retained Earnings | -$34.3Mn/m | -$32.5Mn/m | -$31.0Mn/m | -$29.3Mn/m | -$27.8Mn/m | -$26.1Mn/m | -$24.4Mn/m | -$22.8Mn/m |
Not reported in any period shown, so not listed: Inventory, Goodwill, Long-Term Debt.
CDIOW Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'25Filing | Q3'25Filing | Q2'2510-Q | Q1'2510-Q | Q4'24Filing |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$1.5Mn/m | -$1.3Mn/m | -$1.6Mn/m | -$1.4Mn/m | -$1.4Mn/m | -$1.6Mn/m | -$1.4Mn/m | -$1.4Mn/m |
| Depreciation & Amortization | $6K-85.2% | $6K-34.1% | $6K-87.8% | $44K+726.7% | $40K+741.4% | $8K+77.0% | $45K+848.0% | $5K+11.4% |
| Stock-Based Compensation | N/A | N/A | $25K-19.2% | N/A | N/A | N/A | $31K-98.8% | N/A |
| Capital Expenditures | $0-100.0% | $0-100.0% | $2K-69.6% | $0-100.0% | $163K+600.5% | $19K-88.9% | $6K-71.0% | $4K-99.3% |
| Free Cash Flow | -$1.5Mn/m | -$1.3Mn/m | -$1.6Mn/m | -$1.4Mn/m | -$1.6Mn/m | -$1.6Mn/m | -$1.4Mn/m | -$1.4Mn/m |
| Investing Cash Flow | -$60Kn/m | -$47Kn/m | -$64Kn/m | -$78Kn/m | -$258Kn/m | -$36Kn/m | -$47Kn/m | -$55Kn/m |
| Financing Cash Flow | -$67K-268.8% | -$101Kn/m | $3.6M+8.6% | $196K-97.3% | $40K-97.9% | -$115K-109.9% | $3.3M+109.1% | $7.3Mn/m |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
CDIOW Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'25Filing | Q3'25Filing | Q2'2510-Q | Q1'2510-Q | Q4'24Filing |
|---|---|---|---|---|---|---|---|---|
| Operating Margin | -48193.8% | -27950.5% | -66598.4% | -41159.5% | -59950.9% | -22457.5% | -173463.8% | -33608.2% |
| Net Margin | -48254.3% | -28012.5% | -66722.3% | -41219.9% | -60053.8% | -22517.7% | -173943.0% | -33672.6% |
| Return on Equity | -30.3%-9.3pp | -20.2%-2.9pp | -20.1%-5.7pp | -21.0%-5.1pp | -21.0%+17.3pp | -17.3%+24.6pp | -14.4%+122.7pp | -15.9%+31.1pp |
| Return on Assets | -28.5%-9.0pp | -18.9%-2.8pp | -18.7%-5.4pp | -18.9%-4.6pp | -19.5%+12.0pp | -16.2%+16.0pp | -13.3%+82.9pp | -14.3%+16.8pp |
| Current Ratio | 17.44+0.1x | 17.15-6.4x | 15.76-3.7x | 9.79-4.1x | 17.39+8.9x | 23.55+17.9x | 19.49+15.7x | 13.92+10.6x |
| Liabilities-to-Equity | 0.060.0x | 0.070.0x | 0.070.0x | 0.110.0x | 0.08-0.1x | 0.07-0.2x | 0.08-0.3x | 0.11-0.4x |
| Asset Turnover | 0.000.0x | 0.000.0x | 0.000.0x | 0.000.0x | 0.000.0x | 0.000.0x | 0.000.0x | 0.000.0x |
| FCF Margin | -42225.6% | -25044.1% | -58357.2% | -38308.0% | -54509.7% | -21273.1% | -149562.6% | -30938.2% |
Not reported in any period shown, so not listed: Gross Margin, Debt-to-Equity.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Where Cardio Diagnostics Holdings Inc. Warrant Ranks
Frequently Asked Questions
Cardio Diagnostics Holdings Inc. Warrant (CDIOW) reported $15K in total revenue for fiscal year 2025. This represents a -57.5% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
Cardio Diagnostics Holdings Inc. Warrant (CDIOW) revenue declined by 57.5% year-over-year, from $35K to $15K in fiscal year 2025.
No, Cardio Diagnostics Holdings Inc. Warrant (CDIOW) reported a net loss of $6.5M over the trailing 12 months to September 30, 2026. In fiscal year 2025 it reported a net loss of $6.5M.
Cardio Diagnostics Holdings Inc. Warrant (CDIOW) had EBITDA of -$6.4M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
Cardio Diagnostics Holdings Inc. Warrant (CDIOW) has a return on equity of -93.2% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
Cardio Diagnostics Holdings Inc. Warrant (CDIOW) recorded an outflow of $5.9M in free cash flow during fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
Cardio Diagnostics Holdings Inc. Warrant (CDIOW) recorded an outflow of $5.7M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
Cardio Diagnostics Holdings Inc. Warrant (CDIOW) had $7.8M in total assets as of fiscal year 2025, including both current and long-term assets.
Cardio Diagnostics Holdings Inc. Warrant (CDIOW) invested $187K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
Cardio Diagnostics Holdings Inc. Warrant (CDIOW) invested $641K in research and development during fiscal year 2025.
Cardio Diagnostics Holdings Inc. Warrant (CDIOW) had a current ratio of 9.79 as of fiscal year 2025, which is generally considered healthy.
Cardio Diagnostics Holdings Inc. Warrant (CDIOW) had a liabilities-to-equity ratio of 0.11 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity. No debt-to-equity ratio is shown for fiscal year 2025, because the filing data we hold for that year carries no long-term debt figure.
Cardio Diagnostics Holdings Inc. Warrant (CDIOW) had a return on assets of -83.7% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
At the end of fiscal year 2025, Cardio Diagnostics Holdings Inc. Warrant (CDIOW) held $0 in cash, cash equivalents and investments, and reported an operating cash outflow of $5.7M over that year. Dividing the one by the other, the reported balance equals about 0 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
Cardio Diagnostics Holdings Inc. Warrant (CDIOW) has a Piotroski F-Score of 2 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Cardio Diagnostics Holdings Inc. Warrant (CDIOW) reported a net loss of $6.5M while operations used $5.7M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Cardio Diagnostics Holdings Inc. Warrant (CDIOW) reported an operating loss of $6.5M against $15K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.